Highlights: CME Group Inc.

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Sales forecast by analysts have been recently revised upwards.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses: CME Group Inc.

  • The company's earnings growth outlook lacks momentum and is a weakness.
  • The firm trades with high earnings multiples: 26.27 times its 2025 earnings per share.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The company appears highly valued given the size of its balance sheet.
  • The company is highly valued given the cash flows generated by its activity.
  • Over the past twelve months, analysts' opinions have been revised negatively.

Ratings Chart: CME Group Inc.

Source: Surperformance

ESG chart: CME Group Inc.

Source: MSCI

Fundamentals (Composite) Global Valuation (Composite) Financial estimates revisions (Composite) Capi.($)
9.93TCr
2.92TCr
1.21TCr
1.05TCr
900.85Cr
587.07Cr
502.22Cr
- 394Cr
215.52Cr
Average 1.97TCr
Weighted average by Cap.
See all sector ratings
Investor (Composite)
Trader (Composite)
ESG MSCI
BBB

Financials

Revenue growth
EPS growth
Capital Efficiency (Composite)
Net Margin
Financial Health (Composite)

Valuation

P/E
EV/Revenue
EV/EBITDA
PBR
Dividend Yield

Revisions

Revenue revisions (1 year)
Revenue revisions (4 months)
Revenue revisions (1 month)
EPS revisions (1 year)
EPS revisions (4 months)

Consensus

Analysts' buy/sell recommendations
Analysts' recommendations evolution (4 months)
Analysts' target price
Analysts' target price evolution (4 months)
Analysts' target price evolution (1 year)

Business Predictability

Surprise rates
Analysts' coverage
Analysts' recommendations divergence
Analysts' Target price divergence
Financial estimates divergence

ESG

Environment
Social
Governance
Controversy
Ethical controversies
Human rights controversies
Tax subsidies controversies
Sharia compliant

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. CME Stock
  4. Ratings CME Group Inc.